Sacu S, Varga A, Michels S, Weigert G, Polak K, Vécsei-Marlovits P V, Schmidt-Erfurth U
Medical University of Vienna, Department of Ophthalmology, Vienna, Austria.
Br J Ophthalmol. 2008 Oct;92(10):1347-51. doi: 10.1136/bjo.2008.137885. Epub 2008 Jun 27.
To compare early treatment effect of reduced fluence versus standard photodynamic therapy (rPDT, sPDT, respectively) in combination with intravitreal triamcinolone (IVTA) in neovascular age-related macular degeneration.
Forty patients received either sPDT (group A, n = 20) or rPDT (group B, n = 20) each followed by same-day 4 mg IVTA. Patients were examined at baseline, day 1, week 1, 4 and 12. Main outcomes were visual acuity, central retinal thickness (CRT), choroidal perfusion and macular sensitivity (MS).
Baseline characteristics were well balanced in both groups (p>0.05). At week 12, patients in group A had a mean loss of -3.7 letters compared with a gain of 3.4 letters in group B (p = 0.04, between both groups). Both treatment groups showed a similar course regarding CRT as well as MS (p>0.05). In 70% (14/20) of group A and 15% (3/20) of group B, a choroidal hypoperfusion in the area of treatment was observed after treatment (p<0.001). In 70% of group A and 55% of group B, a repeat treatment was indicated at week 12 (p = 0.55).
At month 3, the rPDT+IVTA group showed a significantly better visual outcome, less alteration of the choroid and a trend for lower recurrence rate than the sPDT+IVTA group. Further follow-up of this study will provide information on long-term functional results and treatment durability.
比较低能量光动力疗法(rPDT)与标准光动力疗法(sPDT)联合玻璃体内注射曲安奈德(IVTA)治疗新生血管性年龄相关性黄斑变性的早期治疗效果。
40例患者分别接受sPDT(A组,n = 20)或rPDT(B组,n = 20)治疗,随后同一天给予4mg IVTA。在基线、第1天、第1周、第4周和第12周对患者进行检查。主要观察指标为视力、中心视网膜厚度(CRT)、脉络膜灌注和黄斑敏感度(MS)。
两组的基线特征平衡良好(p>0.05)。在第12周时,A组患者平均视力下降3.7个字母,而B组患者平均视力提高3.4个字母(两组之间p = 0.04)。两个治疗组在CRT和MS方面显示出相似的变化过程(p>0.05)。治疗后,A组70%(14/20)和B组15%(3/20)的治疗区域出现脉络膜灌注不足(p<0.001)。在第12周时,A组70%和B组55%的患者需要再次治疗(p = 0.55)。
在第3个月时,rPDT+IVTA组的视力结果明显优于sPDT+IVTA组,脉络膜改变较少,复发率也有降低趋势。本研究的进一步随访将提供关于长期功能结果和治疗持久性的信息。